AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
clevidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium channel blockers, nifedipine derivatives | 674 | 167221-71-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a calcium channel blocker and antihypertensive agent
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.65 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.58 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 142 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.30 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK | 21 | |||
| kinase-selectivity-class | AXL,BRAF,GRK2,PDK4,PIK3CB,PIK3CD | 6 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 1, 2008 | FDA | MEDICINES CO |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C08CA16 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
| FDA CS | M0006414 | Dihydropyridines |
| FDA MoA | N0000000069 | Calcium Channel Antagonists |
| FDA EPC | N0000175421 | Dihydropyridine Calcium Channel Blocker |
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
Related Drugs by ATC class:
C08CA Dihydropyridine derivatives 17 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Tachyarrhythmia | contraindication | 6285003 | |
| Minimal change disease | contraindication | 44785005 | DOID:10966 |
| Low blood pressure | contraindication | 45007003 | |
| Pancreatitis | contraindication | 75694006 | DOID:4989 |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Severe Aortic Valve Stenosis | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 0.56 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4028719 | VUID |
| N0000178415 | NUI |
| D08892 | KEGG_DRUG |
| 233603 | RXNORM |
| C0766108 | UMLSCUI |
| CHEBI:135738 | CHEBI |
| CHEMBL1237132 | ChEMBL_ID |
| DB04920 | DRUGBANK_ID |
| C118563 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7468 | IUPHAR_LIGAND_ID |
| 7490 | INN_ID |
| 19O2GP3B7Q | UNII |
| 153994 | PUBCHEM_CID |
| 147455 | MMSL |
| d07312 | MMSL |
| 012824 | NDDF |
| 439471002 | SNOMEDCT_US |
| 439624003 | SNOMEDCT_US |
| 4028719 | VANDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-610 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
| Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-610 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
| Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-611 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
| Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-611 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 25 sections |
| Cleviprex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 18124-011 | EMULSION | 0.50 mg | INTRAVENOUS | NDA | 29 sections |